Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy.

MLA

Bauer, Todd M., et al. “Carbohydrate Antigen 19-9 Is a Prognostic and Predictive Biomarker in Patients with Advanced Pancreatic Cancer Who Receive Gemcitabine-Containing Chemotherapy.” Cancer (0008543X), vol. 119, no. 2, Jan. 2013, pp. 285–92. EBSCOhost, https://doi.org/10.1002/cncr.27734.

APA

Bauer, T. M., El, R. B. F., Li, X., Hammad, N., Philip, P. A., Shields, A. F., Zalupski, M. M., & Bekaii, S. T. (2013). Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. Cancer (0008543X), 119(2), 285–292. https://doi.org/10.1002/cncr.27734

Chicago

Bauer, Todd M., Rayes, Bassel F. El, Xiaobai Li, Nazik Hammad, Philip A. Philip, Anthony F. Shields, Mark M. Zalupski, and Saab, Tanios Bekaii. 2013. “Carbohydrate Antigen 19-9 Is a Prognostic and Predictive Biomarker in Patients with Advanced Pancreatic Cancer Who Receive Gemcitabine-Containing Chemotherapy.” Cancer (0008543X) 119 (2): 285–92. doi:10.1002/cncr.27734.